What is William Blair's Estimate for MaxCyte Q2 Earnings?

MaxCyte, Inc. (NASDAQ:MXCT - Free Report) - Equities researchers at William Blair reduced their Q2 2025 earnings per share (EPS) estimates for MaxCyte in a note issued to investors on Thursday, May 8th. William Blair analyst M. Larew now anticipates that the company will earn ($0.11) per share for the quarter, down from their previous estimate of ($0.09). The consensus estimate for MaxCyte's current full-year earnings is ($0.42) per share. William Blair also issued estimates for MaxCyte's Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.42) EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.39) EPS.

A number of other equities analysts also recently issued reports on MXCT. Stifel Nicolaus cut their price target on MaxCyte from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Wednesday, March 12th. BTIG Research set a $6.00 target price on MaxCyte and gave the company a "buy" rating in a research report on Wednesday, March 12th.

MaxCyte Stock Performance

Shares of MaxCyte stock traded up $0.05 during trading hours on Monday, reaching $2.28. The company's stock had a trading volume of 278,999 shares, compared to its average volume of 555,074. The company has a market capitalization of $241.88 million, a P/E ratio of -6.69 and a beta of 1.38. The stock's fifty day simple moving average is $2.73 and its two-hundred day simple moving average is $3.58. MaxCyte has a one year low of $2.10 and a one year high of $5.26.

MaxCyte (NASDAQ:MXCT - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.10). The company had revenue of $10.39 million for the quarter, compared to analysts' expectations of $9.05 million. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC raised its holdings in shares of MaxCyte by 123.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,564 shares of the company's stock worth $31,000 after purchasing an additional 4,173 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of MaxCyte in the fourth quarter valued at $56,000. Kwmg LLC purchased a new position in shares of MaxCyte during the 1st quarter valued at $40,000. Prudential Financial Inc. bought a new position in shares of MaxCyte during the 4th quarter worth $65,000. Finally, Catalyst Funds Management Pty Ltd bought a new position in shares of MaxCyte during the 4th quarter worth $74,000. 68.81% of the stock is owned by institutional investors.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.